Can I Take Vitamin B6 with Jardiance (Empagliflozin)?

The Short Answer: Is Vitamin B6 Safe with Jardiance?

For most adults, taking vitamin B6 at standard dietary or low-dose supplemental levels alongside Jardiance poses no meaningful drug interaction risk. Empagliflozin does not rely on the enzymatic pathways that pyridoxine affects, and pyridoxine does not act on SGLT2 transporters in the kidney [1]. The concern that does exist is entirely dose-dependent: high-dose B6 supplementation, typically defined as sustained intake above 200 mg per day, can cause peripheral sensory neuropathy on its own [2].

Because Jardiance is prescribed predominantly to people with type 2 diabetes, a population where up to 50% already carry some degree of peripheral neuropathy, any supplement that independently damages peripheral nerves deserves a careful look [3].

Why People Ask About This Combination

Many people taking Jardiance for type 2 diabetes, heart failure, or chronic kidney disease (CKD) also take B-vitamin stacks to support nerve health or to offset perceived deficiencies. B6 is frequently included in "nerve support" supplements marketed to people with diabetes. The question of safety is reasonable. The answer requires separating the pharmacokinetic question (do these compounds interfere with each other's absorption, metabolism, or excretion?) from the pharmacodynamic question (can they cause harm through overlapping biological effects?).

How Empagliflozin Is Metabolized

Empagliflozin is metabolized primarily through glucuronidation by the UDP-glucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7, producing three glucuronide metabolites [4]. It is not a substrate of CYP3A4, CYP2C8, or CYP2C9. Vitamin B6 in its active form (pyridoxal-5-phosphate) is produced by hepatic phosphorylation and does not induce or inhibit UGT enzymes at physiologic or supplemental doses. These two compounds simply do not share metabolic bottlenecks [5].

Understanding Vitamin B6: Forms, Doses, and Biological Role

Vitamin B6 refers to a family of six related compounds, all convertible in the body to the active coenzyme pyridoxal-5-phosphate (PLP). PLP is involved in over 100 enzymatic reactions, including amino acid transamination, heme synthesis, and neurotransmitter production (serotonin, dopamine, GABA) [6].

Dietary vs. Supplemental Intake

The recommended dietary allowance (RDA) for B6 is 1.3 mg per day for adults aged 19 to 50 and 1.7 mg per day for men over 50, per the NIH Office of Dietary Supplements [7]. Most multivitamins contain 2 to 10 mg. Therapeutic "nerve support" products commonly supply 50 to 100 mg. Some compounded formulations or high-dose B-complex products go as high as 500 mg per day.

The tolerable upper intake level (UL) set by the Food and Nutrition Board is 100 mg per day for adults [7]. This UL exists specifically because of the documented neuropathy risk at higher doses.

When B6 Becomes a Problem

Sensory neuropathy from pyridoxine toxicity was first characterized in a 1983 case series by Schaumburg et al. Published in the New England Journal of Medicine, which described seven patients who developed ataxia and severe sensory neuropathy after taking 2,000 to 6,000 mg of pyridoxine daily [8]. Later reports extended the risk to chronic intake at lower doses. A 2023 systematic review found that peripheral neuropathy has been reported at sustained daily doses as low as 50 mg in sensitive individuals, though the majority of cases involved doses above 500 mg [2].

How Empagliflozin Works and Why Neuropathy Matters

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, reducing glucose reabsorption and lowering blood glucose independent of insulin [1]. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin reduced the risk of cardiovascular death by 38% relative to placebo (hazard ratio 0.62, 95% CI 0.49 to 0.77) in adults with type 2 diabetes and established cardiovascular disease [9].

Diabetic Peripheral Neuropathy as a Baseline Risk

Adults with type 2 diabetes already face a substantial neuropathy burden. Estimates from the CDC suggest that between 30% and 50% of people with diabetes will develop some form of peripheral neuropathy over their lifetime [3]. Symptoms overlap considerably with B6 toxicity neuropathy: numbness, tingling, burning pain, and loss of vibration sense in a stocking-and-glove distribution.

This overlap is clinically significant. If a patient on Jardiance develops new tingling in their feet, the differential diagnosis includes worsening diabetic neuropathy, B6 toxicity, uremic neuropathy (relevant in CKD patients), and other causes. High-dose B6 supplementation adds a preventable variable to an already complicated picture.

SGLT2 Inhibitors and Neuropathy: What the Data Show

SGLT2 inhibitors as a class have not been shown to cause or worsen peripheral neuropathy. The FDA label for empagliflozin does not list neuropathy as an adverse effect [4]. The EMPEROR-Reduced trial (N=3,730), which evaluated empagliflozin 10 mg in heart failure with reduced ejection fraction, reported no neuropathy signal in its adverse event profile [10]. Jardiance does not damage nerves. High-dose B6 can. That asymmetry shapes the clinical guidance below.

Pharmacokinetic Interaction Analysis: Does B6 Change How Jardiance Works?

No published pharmacokinetic study has examined the specific combination of pyridoxine and empagliflozin. Based on their respective metabolic profiles, a clinically meaningful pharmacokinetic interaction is unlikely for the following reasons.

Absorption

Empagliflozin is absorbed in the small intestine with a bioavailability of approximately 86% [4]. Pyridoxine is absorbed via a non-saturable passive diffusion mechanism throughout the small intestine [6]. Neither compound depends on the same transporters, and they do not chelate each other or compete for intestinal binding sites. Timing of co-administration is not a clinical concern.

Protein Binding and Distribution

Empagliflozin is approximately 86.2% protein-bound, predominantly to albumin [4]. Pyridoxal-5-phosphate is also albumin-bound. Theoretically, highly protein-bound compounds can displace each other. At physiologic and supplemental PLP concentrations, this displacement is negligible and has not been documented as clinically meaningful for pyridoxine with any drug in the UGT-metabolized class.

Renal Excretion

Empagliflozin promotes glucose excretion via SGLT2 blockade but is itself cleared predominantly by glucuronidation and then renal excretion of its metabolites [4]. Vitamin B6 metabolites, primarily 4-pyridoxic acid, are also renally cleared [7]. In patients with advanced CKD (eGFR <30 mL/min/1.73 m²), B6 metabolites may accumulate modestly, but this does not alter empagliflozin clearance [11].

The Real Risk: Pharmacodynamic Overlap at High B6 Doses

The interaction concern here is pharmacodynamic, not pharmacokinetic. Both conditions, diabetic neuropathy and pyridoxine toxicity neuropathy, damage the same peripheral sensory fibers. Jardiance does not cause neuropathy, but the population taking it already has elevated neuropathy risk. Layering high-dose B6 supplementation onto that baseline risk is the clinical problem.

What "High Dose" Means in Practice

• 1 to 10 mg/day: Typical multivitamin range. No neuropathy risk documented at this range [7].
• 10 to 100 mg/day: Common in B-complex and "nerve support" products. Within the tolerable upper intake level. No well-documented neuropathy cases at this dose range in short-term use.
• 100 to 200 mg/day: At or above the UL. Risk increases with duration. The 2023 systematic review by Vrolijk et al. Identified cases in this range with chronic use exceeding 12 months [2].
• Above 200 mg/day: Clear dose-dependent neuropathy risk. A case series in the British Medical Journal described sensory neuropathy in patients taking 200 mg/day for longer than 6 months [12].
• Above 500 mg/day: High risk. Most textbook cases of B6 toxicity neuropathy fall in this range [8].

Symptoms to Watch For

Patients on Jardiance taking more than 100 mg of B6 daily should know to report: new or worsening tingling or numbness in the hands or feet, burning pain, difficulty with fine motor tasks, or unsteady gait. These symptoms warrant stopping high-dose B6 and arranging a neurology or endocrinology consult to disentangle the cause.

Specific Populations: CKD and Heart Failure Patients on Jardiance

The 2023 FDA approval of empagliflozin for CKD (eGFR ≥20 mL/min/1.73 m²) expanded the Jardiance patient population to include people with significant renal impairment [4]. This matters for B6 because renal clearance of pyridoxal-5-phosphate metabolites is reduced in CKD, potentially raising plasma PLP levels for a given oral dose.

CKD-Specific Considerations

A pharmacokinetic study published in the American Journal of Kidney Diseases found that plasma PLP concentrations were significantly higher in patients with stage 3 to 4 CKD compared to controls given equivalent oral B6 doses [11]. This means CKD patients on Jardiance face a higher effective B6 exposure for the same supplement dose, shifting the risk threshold downward. Patients with eGFR <45 mL/min/1.73 m² should aim to keep B6 supplementation at or below 25 to 50 mg per day and discuss even this range with their prescriber.

Heart Failure Patients

In the EMPEROR-Reduced trial, empagliflozin 10 mg daily reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75, 95% CI 0.65 to 0.86) [10]. Heart failure patients commonly take multiple supplements. B6 at standard multivitamin doses is not a concern in this group, but high-dose B6 should be flagged to the prescribing cardiologist.

Monitoring Framework for Patients Taking Both

The table below summarizes the HealthRX clinical monitoring framework for adults taking empagliflozin who are also using or considering vitamin B6 supplementation. This framework was developed by the HealthRX medical team based on FDA labeling, NIH dietary reference intakes, and published neuropathy case literature.

| B6 Daily Dose | Risk Level | Recommended Action | |---|---|---| | 1 to 10 mg | Low | No additional monitoring beyond standard Jardiance care | | 10 to 100 mg | Low to moderate | Annual neuropathy screen; disclose to prescriber | | 100 to 200 mg | Moderate | Disclose to prescriber; consider reducing to <100 mg; 6-month neuropathy check | | Above 200 mg | High | Discuss with prescriber before continuing; taper dose; neurology consult if symptoms present | | Above 500 mg | Very high | Stop and contact prescriber; rule out B6 toxicity if neuropathy symptoms exist |

What the Guidelines Say

The American Diabetes Association (ADA) 2024 Standards of Care state: "Supplementation with antioxidants, such as vitamins E and C and carotene, is not advised due to lack of evidence of efficacy and concern related to long-term safety. Vitamin B supplementation should follow standard dietary intake recommendations unless a documented deficiency exists." [13]

The Endocrine Society does not list vitamin B6 as a supplement requiring routine restriction in patients on SGLT2 inhibitors, but its 2023 clinical practice guideline on diabetic neuropathy advises clinicians to "exclude modifiable causes of neuropathy, including toxic exposures and nutritional excess, before attributing neuropathy progression to diabetes alone." [14]

These two statements together support a straightforward clinical approach: low-dose B6 is fine; high-dose B6 requires active management.

Practical Guidance: What to Tell Your Doctor

Before starting or continuing B6 supplementation alongside Jardiance, bring the supplement bottle to your next visit. Your prescriber needs to know:

1. The specific form of B6 in the product (pyridoxine hydrochloride vs. Pyridoxal-5-phosphate).
2. The dose per serving and how many servings you take daily.
3. Whether any other supplements or medications in your regimen contain B6 (many multivitamins and B-complex products contribute additional milligrams).
4. Whether you have any current neuropathy symptoms.

Your prescriber will likely order a baseline foot exam or monofilament test if one has not been done recently. The Michigan Neuropathy Screening Instrument (MNSI) is a validated 15-item questionnaire and physical exam tool used in clinical practice and in large diabetes trials including ACCORD [15].

Drug Interactions That Genuinely Require Dose Separation with Jardiance

Empagliflozin does have documented interactions with other agents worth knowing. Rifampin (a CYP inducer and UGT inducer) reduces empagliflozin AUC by approximately 35% [4]. Loop diuretics combined with empagliflozin increase volume depletion risk. Insulin and sulfonylureas increase hypoglycemia risk. None of these apply to vitamin B6, which reinforces that B6 is not among the pharmacokinetically significant interactions for this drug.

Frequently Asked Questions